On-Line Haemodiafiltration versus Haemodialysis: Stable Haematocrit with Less Erythropoietin and Improvement of Other Relevant Blood ParametersVaslaki L.a · Major L.b · Berta K.c · Karatson A.d · Misz M.e · Pethoe F.f · Ladanyi E.g · Fodor B.g · Stein G.h · Pischetsrieder M.i · Zima T.k · Wojke R.j · Gauly A.j · Passlick-Deetjen J.j
a–gDialysis Centres of Fresenius Medical Care in Hungary,aSopron, bEsztergom, cBudapest, dPécs, eEger, fSalgótarján, gMiskolc, Hungary; hUniversity of Jena, Jena, iUniversity of Erlangen, Erlangen, and jFresenius Medical Care, Bad Homburg, Germany; kUniversity of Prague, Prague, Czech Republic
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Controlled randomised studies to prove improved cardiovascular stability and improved anaemia management during on-line haemodiafiltration (oHDF) are scarce. Methods: 70 patients were treated with both haemodialysis (HD) and oHDF in a cross-over design during 2 × 24 weeks at a dialysis dose of eKt/V≧1.2. Patients randomised into group A started on HD and switched over to oHDF, whereas patients in group B began with oHDF and were treated with HD afterwards. Intradialytic morbid events (IME), such as symptomatic hypotension or muscle cramps, were noted in case of appearance. Blood parameters reflecting anaemic status, phosphate status, lipid metabolism, oxidative stress, and accumulation of advanced glycation end products were recorded either monthly or at the end of each study phase. Results: The mean incidence of IME was 0.15 IME per treatment, and there was no statistical difference between oHDF and HD. A higher haematocrit (oHDF 31.5% vs. HD 30.5%, p < 0.01) at a lower erythropoietin dose (oHDF 4,913 vs. HD 5,492 IU/week, p = 0.02) was found during oHDF, when the sequence of HD and oHDF had not been taken into account. For the study groups, the results were less distinct: in group A, a higher haematocrit (HD 30.4% vs. oHDF 32.0%, p < 0.01) at a comparable erythropoietin dose (HD 5,421 vs. oHDF 5,187 IU/week, ns) was observed during oHDF, whereas in group B an identical haematocrit (oHDF 30.8% vs. HD 30.7%, ns) was achieved at a reduced erythropoietin dose (oHDF 4,622 vs. HD 5,568 IU/week, p < 0.01). During oHDF, lower levels of free and protein-bound pentosidine and of serum phosphate were found. Conclusion: In contrast to other studies, no benefit regarding cardiovascular stability for oHDF was found, but oHDF could well offer a potential benefit regarding anaemia correction, inflammation, oxidative stress, lipid profiles, and calcium-phosphate product.
© 2006 S. Karger AG, Basel
- Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Muller W: On-line hemodiafiltration with pre- and postdilution: A comparison of efficacy. Int J Artif Organs 1997;20:81–90.
- Maduell F, Navarro V, Cruz C, et al: Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis 2002;40:582–589.
Castro R, Morgado T: On-line haemodiafiltration: comparative study with classic haemodialysis. Rev Port Nefrol Hipert 1998;13:37–47.
- Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999;55:286–293.
- Maduell F, del Pozo C, Garcia H, et al: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999;14:1202–1207.
- Wizemann V, Lotz C, Techert F, Uthoff S: On-line haemodifiltration versus low-flux haemodialysis. A prospective randomised study. Nephrol Dial Transplant 2000;15(suppl 1):43–48.
- Bonforte G, Grillo P, Zerbi S, Surian M: Improvement of anaemia in hemodialysis patients treated by hemodiafiltration with high volume on-line prepared substitution fluid. Blood Purif 2002;20:357–363.
- Pizzarelli F, Cerrai T, Dattolo P, Tetta C, Maggiore Q: Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. Nephrol Dial Transplant 1998;13:363–369.
- Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207–1211.
- Vaslaki L, Karatson A, Voros P, et al: Can sterile and pyrogen-free on-line substitution fluid be routinely delivered? A multicentric study on the microbiological safety of on-line haemodiafiltration. Nephrol Dial Transplant 2000;15(suppl 1):74–78.
- Canaud B, Wizemann V, Pizzarelli F, et al: Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant 2001;16:2181–2187.
- Ward RA, Schmidt B, Hullin J, Hillebrand G, Samtleben W: A comparison of on-line haemodiafiltration versus high-flux haemodialyis. A prospective clinical study. J Am Soc Nephrol 2000;11:2344–2350.
- Dellana F, Wuepper A, Baldamus CA: Internal filtration – advantage in haemodialysis. Nephrol Dial Transplant 1996;11(suppl 2):83–86.
- Ahrenholz PG, Winkler RE, Michelsen A, Lang DA, Bowry SK: Dialysis membrane dependent removal of middle molecules during hemodiafiltration: The β2-microglobulin/albumin relationship. Clin Nephrol 2004;62:21–28.
- Vaslaki L, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D: On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: Results from a multicenter cross-over study. Artif Org 2005;29:406–412.
- Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescent detection. J Chromatogr Biomed Appl 1987;422:43–52.
- Zhang X, Frischmann M, Kientsch-Engel R, Steinmann K, Stopper H, Niwa T, Pischetsrieder M: Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005;43:503–511.
- Stein G, Franke S, Mahiout A, Schneider S, et al: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999–1008.
- Hills M, Armitage P: The two period cross-over trial. Br J Clin Pharmacol 1979;8:7–20.
- Cheung AK, Yan G, Greene T, et al: Seasonal variations in clinical and laboratory variables among hemodialysis patients. J Am Soc Nephrol 2002;13:2345–2352.
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2).
- Di Iorio BR, Stellato D, De Santo NG, Cirillo M: Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 2004;22:423–427.
- Kovacic V, Kovacic V: Seasonal variations of clinical and biochemical parameters in chronic haemodialysis. Ann Acad Med Singapore 2004;33:763–768.
- Lin CL, Huang CC, Yu CC, et al: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003;3:524–531.
Gerdemann A, Wagner Z, Solf A, et al: Plasma levels of dialysis duration predict mortality: Evidence for the complexity of dialysate quality. Nephrol 2004;15:770–779.
- Tomo T, Matsuyama K, Nasu M: Effect of haemodiafiltration against radical stress in the course of blood purification. Blood Purif 2004;22(suppl 2):72–77.
- Bonomini M, Ballone E, Di Stante S, Bucciarelli T, Dottori S, Arduini A, Urbani A, Sirolli V: Removal of uraemic plasma factor(s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells. Nephrol Dial Transplant 2004;19:68–74.
- Beerenhout C, Kooman J, Luik A, Jeuken-Mertens S, van der Sande F, Leunissen K: Optimizing renal replacement therapy – a case for online filtration therapies? Nephrol Dial Transplant 2002;17:2065–2070.
- Stein G, Franke S, Sperschneider H, et al: Decrease in serum pentosidine levels of ESRD patients during polysulfone haemodialysis. Nephrol Dial Transplant 1999;14:1606–1608.
- Kalousová M, Škrha J, Zima T: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597–604.
- Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770–779.
- Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara A, Rodriguez M, Aljama P: Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46:68–77.
- Zehnder C, Gutzwiller JP, Renggli K, Hemodiafiltration – a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152–159.
- Minutolo R, Bellizzi V, Cioffi M, et al: Postdialytical rebound of serum phosphorus: pathogenetic and clinical insight. J Am Soc Nephrol 2002;13:1046–1054.
- Donauer J, Schweiger C, Rumberger B, Krumme B, Boehler J: Reduction of hypotensive side effects during online-haemodiafiltration and low-temperature haemodialysis. Nephrol Dial Transplant 2003;18:1616–1622.
- Gabutti L, Ferrari N, Giudici G, Mombelli G, Marone C: Unexpected haemodynamic instability associated with standard bicarbonate haemodialyis. Nephrol Dial Transplant 2003;18:2369–2376.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.